Drugs / UCB4594
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06380816 | Jul 2024 → Nov 2029 expected | cervical cancer, clear cell renal carcinoma, colorectal neoplasm, gastric neoplasm +6 | Cancer Research UK | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB4594 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06380816 ↗ |
| Modality | Monoclonal antibody | “UCB4594 is a type of drug called a monoclonal antibody.” NCT06380816 ↗ |
| Route | Intravenous | “as an intravenous infusion” NCT06380816 ↗ |
| Target | HLA-G | “It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G)” NCT06380816 ↗ |